Objective: Among perinatally infected children, the effects of certain alleles of the CCR5 and CCR2 genes on the rate of disease progression remain unclear. We addressed the effects of CCR5-Delta32 and CCR2-641 in an international meta-analysis. Methods: Genotype data were contributed from 10 studies with 1317 HIV-1-infected children (7263 person-years of follow-up). Time-to-event analyses were performed stratified by study and racial group. Endpoints included progression to clinical AIDS, death, and death after the diagnosis of clinical AIDS. The time-dependence of the genetic effects was specifically investigated. Results: There was large heterogeneity in the observed rates of disease progression between different cohorts. For progression to clinical AIDS, both CCR5-Delta32 and CCR2-641 showed overall non-significant trends for protection [hazard ratios 0.84, 95% confidence interval (0) 0.58-1.23; and 0.87, 95% CI 0.67-1.14, respectively]. However, analyses of survival showed statistically significant time-dependence. No deaths occurred among CCR5-Delta32 carriers in the first 3 years of life, whereas there was no protective effect (hazard ratio 0.95; 95% CI 0.43-2.10) in later years (P = 0.01 for the time-dependent model). For CCR2-641, the hazard ratio for death was 0.69 (95% CI 0.39-1.21) in the first 6 years of life and 2.56 (95% CI 1.26-5.20) in subsequent years (P < 0.01 for the time-dependent model). CCR5-Delta32 and CCR2-641 offered no clear protection after clinical AIDS had developed. Conclusion: The CCR5-Delta32 and CCR2-641 alelles are associated with a decreased risk of death among perinatally infected children, but only for the first years of life. (C) 2003 Lippincott Williams Wilkins
Effects of CCR5-Delta 32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis
DE ROSSI, ANITA;
2003
Abstract
Objective: Among perinatally infected children, the effects of certain alleles of the CCR5 and CCR2 genes on the rate of disease progression remain unclear. We addressed the effects of CCR5-Delta32 and CCR2-641 in an international meta-analysis. Methods: Genotype data were contributed from 10 studies with 1317 HIV-1-infected children (7263 person-years of follow-up). Time-to-event analyses were performed stratified by study and racial group. Endpoints included progression to clinical AIDS, death, and death after the diagnosis of clinical AIDS. The time-dependence of the genetic effects was specifically investigated. Results: There was large heterogeneity in the observed rates of disease progression between different cohorts. For progression to clinical AIDS, both CCR5-Delta32 and CCR2-641 showed overall non-significant trends for protection [hazard ratios 0.84, 95% confidence interval (0) 0.58-1.23; and 0.87, 95% CI 0.67-1.14, respectively]. However, analyses of survival showed statistically significant time-dependence. No deaths occurred among CCR5-Delta32 carriers in the first 3 years of life, whereas there was no protective effect (hazard ratio 0.95; 95% CI 0.43-2.10) in later years (P = 0.01 for the time-dependent model). For CCR2-641, the hazard ratio for death was 0.69 (95% CI 0.39-1.21) in the first 6 years of life and 2.56 (95% CI 1.26-5.20) in subsequent years (P < 0.01 for the time-dependent model). CCR5-Delta32 and CCR2-641 offered no clear protection after clinical AIDS had developed. Conclusion: The CCR5-Delta32 and CCR2-641 alelles are associated with a decreased risk of death among perinatally infected children, but only for the first years of life. (C) 2003 Lippincott Williams Wilkins| File | Dimensione | Formato | |
|---|---|---|---|
|
2003_AIDS_Ioannidis et al.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Accesso libero
Dimensione
94.67 kB
Formato
Adobe PDF
|
94.67 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




